Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
[{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$12.2 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer, Novo-backed German biotech banks \u20ac11M in liver regeneration push","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"HepaRegeniX"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125\/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Completes Enrollment of Subjects in AXA1665-002 Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"CN Bio","sponsor":"Cambridge University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"CN Bio"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Patent Issuances Covering AXA1665","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Poseida Therapeutics, Inc"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Axcella\u2019s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kaleido Biosciences"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galmed and Ascletis Subsidiary Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ionis Announces third Investigational Antisense Medicine to treat Nonalcoholic Steatohepatitis (NASH) Enters Development","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$303.0 million","newsHeadline":"Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Genevant Sciences"},{"orgOrder":0,"company":"Mitsubishi Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Corporation Life Sciences Granted New US Patent for \"Composition Containing Glutathione as an Active Ingredient for Improvement or Prevention of Non-Alcoholic Fatty Liver\"","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Mitsubishi Corporation"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Acuitas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Alcresta Therapeutics","sponsor":"Linden Capital Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linden Capital Partners Acquires Alcresta Therapeutics, Inc.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Alcresta Therapeutics"}]

Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Alcresta Therapeutics has developed a novel enzyme-based (iLipase) platform, including ALC-079, which is being investigated for the Neonatal Intensive Care Unit for pancreatic immaturity.

            Lead Product(s): ALC-079

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALC-079

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Linden Capital Partners

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 12, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.

            Lead Product(s): LNP-based Gene Therapy

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Acuitas

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            USPTO has granted a patent to Mitsubishi Corporation Life Sciences for a method of improving nonalcoholic fatty liver disease in patients in need of treatment, comprising the administration of a composition containing glutathione as its active ingredient.

            Lead Product(s): Glutathione

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Opitac

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Takeda has exclusive rights to utilize Genevant’s LNP technology in the development and commercialization of specified nonviral gene therapies for up to two undisclosed rare liver diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: $303.0 million

            Deal Type: Collaboration August 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH).

            Lead Product(s): ION455

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ION455

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $330.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The new publication details the potential for the development of EMM compositions that simultaneously target multiple biological pathways and address unmet needs in a range of complex diseases.

            Lead Product(s): AXA1125

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ASC41 is an oral thyroid hormone receptor beta agonist and Aramchol is a novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, linked by a stable amide group. The team will work together combining both the therapies for the treatment of NASH.

            Lead Product(s): ASC41,Aramchol

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC41

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Galmed Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The results include details on the effects of KB174 on microbiome nitrogen metabolism in a clinical study in patients with cirrhosis, improved tolerability for KB174 relative to lactulose, as well as effects of MMTs on bacterial composition in patient samples ex vivo.

            Lead Product(s): KB174

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: KB174

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Data support AXA1665’s potential to address hyperammonemia, amino acid dysregulation and physical dysfunction in subjects with cirrhosis.

            Lead Product(s): AXA1665

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks.

            Lead Product(s): AXA1665

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY